Table 3 Selected phase 1/2 trials for HER2 mutant NSCLC
From: Oncogenic alterations in advanced NSCLC: a molecular super-highway
Trial | Clinical trials ID | Treatments | Objective response rate (%) | Median duration of response (months) | Median overall survival (months) |
|---|---|---|---|---|---|
Zenith20-1 | NCT03318939 | Poziotinib | 27.8 | 5.5 | NR |
Destiny-Lung02 | NCT04644237 | Trastuzumab-deruxtecan 5.4mg/m2 vs 6.4mg/m2 | 53.8 vs 42.9 | Not estimable vs 5.9 | NR |
Liu et al | NCT03605602 | Pyrotinib | 35.7 | 7.3 | 14.3 |